Dive Brief:

简报：

A two-drug regimen involving an experimental cancer immunotherapy from iTeos Therapeutics and GSK

涉及iTeos Therapeutics和GSK的一种实验性癌症免疫疗法的两药方案

didn’t significantly delay tumor progression

并未显著延缓肿瘤进展

in a Phase 2 trial, leading the companies to end development and terminate the collaboration they formed around the drug four years ago.

在一项二期试验中，导致公司结束开发，并终止了他们四年前围绕该药物建立的合作关系。

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to Jemperli alone in people with non-small cell lung cancer. The study showed a “trend below the meaningful threshold” for drug responses in study arms including people with head and neck cancer, the companies said Tuesday..

当与GSK的药物Jemperli联合使用时，这种名为belrestotug、针对TIGIT细胞靶点的免疫疗法，在非小细胞肺癌患者中未能达到预设的无进展生存标准，相较单独使用Jemperli未见显著改善。公司于周二表示，在包括头颈癌患者的研究组中，药物反应显示出“低于有意义阈值的趋势”。

Based on the results, iTeos and GSK are stopping all ongoing trials of belrestotug, including an ongoing Phase 3 study in lung cancer. iTeos is “taking immediate steps to preserve capital” as well as starting a strategic review.

基于研究结果，iTeos 和 GSK 决定停止所有正在进行的 belrestotug 试验，包括一项正在进行的肺癌 III 期研究。iTeos 还在“立即采取措施保护资本”，并开始进行战略评估。

Dive Insight:

深入洞察：

TIGIT became a top target in the biopharmaceutical industry’s efforts over the past decade to expand cancer immunotherapy. The protein is thought to smother immune responses to cancer, and drugmakers believed that blocking it might amplify the effects of the

TIGIT成为生物制药行业过去十年扩大癌症免疫疗法努力的首要目标。该蛋白被认为会抑制对癌症的免疫反应，药物制造商认为阻断它可能会增强

“checkpoint inhibitors” used to treat dozens of tumors

用于治疗数十种肿瘤的“检查点抑制剂”

.

。

That promise sparked a flurry of investment into TIGIT-blocking drugs. Major pharmaceutical companies like

这一承诺引发了对TIGIT阻断药物的大量投资。像 крупных фармацевтических компаний

Roche

罗氏

,

，

Merck & Co.

默克公司

,

，

Bristol Myers Squibb

百时美施贵宝

and

和

Gilead Sciences

吉利德科学公司

all either developed or acquired prospects. GSK

所有前景要么已开发，要么已获取。GSK

paid iTeos $625 million in guaranteed cash

支付了6.25亿美元的保证现金给iTeos

, and promised up to $1.45 billion more, for rights to belrestotug. In a statement at the time, GSK noted how combinations involving the drug and other immunotherapies could “become transformative medicines” for many cancer patients.

，并承诺再提供高达 14.5 亿美元的资金，以获取 belrestotug 的权利。葛兰素史克当时在一份声明中指出，涉及该药物与其他免疫疗法的组合可能成为许多癌症患者的“变革性药物”。

Since then,

自那时以来，

several

若干

important

重要的

studies

研究

failed to show that blocking TIGIT can lead to better outcomes, seeding doubt about the target and pushing

未能证明阻断 TIGIT 会导致更好的结果，从而引发了对该靶点的怀疑并推动了相关研究。

multiple

多个

companies to terminate research. Others continued on, touting early results that met analyst thresholds for success. iTeos and GSK were among them, reporting last year how a combination of belrestotug and Jemperli shrank tumors in

公司终止研究。其他公司则继续前进，吹捧早期结果达到了分析师的成功标准。iTeos 和 GSK 就在其中，他们去年报告了 belrestotug 与 Jemperli 的组合如何使肿瘤缩小。

roughly twice as many people as Jemperli alone

大约是Jemperli单独人数的两倍

in their Phase 2 study in lung cancer, meeting the trial’s primary objective.

在他们针对肺癌的二期研究中，达到了试验的主要目标。

However, the companies didn’t prove those effects would help delay tumor progression. Doing so was a secondary study goal and a key bar for belrestotug to meet for development to continue.

然而，这些公司并未证明这些效果有助于延缓肿瘤进展。做到这一点是次要研究目标，也是贝尔雷索图继续开发需要达到的关键标准。

Tuesday’s decision to end testing eliminates iTeos’ most advanced drug prospect as well as the future payouts it could have received from GSK. Given the “current market conditions,” iTeos will now evaluate a range of strategic alternatives to maximize its share value, CEO Michel Detheux said in a statement..

周二决定停止试验，这使得iTeos最先进的药物前景以及其本可以从GSK获得的未来收益化为泡影。首席执行官米歇尔·德特欧在一份声明中表示，鉴于“当前市场状况”，iTeos现在将评估一系列战略选择，以最大化其股票价值。

Gilead and Arcus still have a TIGIT-blocking drug in Phase 3 testing in a type of cancer of the gastrointestinal tract. Study results are

吉利德和阿库斯公司仍在进行一种针对胃肠道癌症的TIGIT阻断药物的第三阶段测试。研究结果是

expected next year

预计明年

.

。